Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
August 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
Press releases published on August 1, 2025
Orchestra BioMed Announces Pricing of $40 Million Public Offering
GlobeNewswire
·
August 1, 2025
NEW HOPE, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced …
FOXO TECHNOLOGIES INC.’S BIG SOUTH FORK MEDICAL CENTER COMPLETES PERFORMANCE NETWORK AGREEMENT WITH COVENANT HEALTH TO PROVIDE SWING BED SERVICES
GlobeNewswire
·
August 1, 2025
WEST PALM BEACH, FLORIDA, Aug. 01, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that its critical access designated rural hospital, Big South Fork Medical Center located in Oneida, …
Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company’s Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression
GlobeNewswire
·
August 1, 2025
SOLANA BEACH, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (“Artelo” or the “Company”) (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with …
Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders
GlobeNewswire
·
August 1, 2025
SAN DIEGO and TORONTO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF; OTCQB: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy …
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
August 1, 2025
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on August 1, 2025, it awarded …
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
August 1, 2025
CLEVELAND, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule …
NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases
GlobeNewswire
·
August 1, 2025
MOUNTAIN VIEW, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today issued the following statement in response to the Centers for …
BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
GlobeNewswire
·
August 1, 2025
Vast majority of patients dosed completed the full 12-week study Data from more than 2,200 agitation episodes collected Topline data readout anticipated this month NEW HAVEN, Conn., Aug. 01, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI …
Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights
GlobeNewswire
·
August 1, 2025
Updated cash guidance provides runway into at least the middle of calendar 2026 Company remains encouraged by MDNA11 clinical results presented to-date, demonstrating best-in-class potential of our IL-2 superkine by exceeding ORR benchmarks demonstrated …
ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET
GlobeNewswire
·
August 1, 2025
PRINCETON, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2025 financial results on Friday, August 8, 2025, prior to the market open …
Regeneron Reports Second Quarter 2025 Financial and Operating Results
GlobeNewswire
·
August 1, 2025
Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased 29% to $393 million; total EYLEA HD and EYLEA® U.S. net …
BrightSpring Health Services, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year 2025 Guidance
GlobeNewswire
·
August 1, 2025
LOUISVILLE, Ky., Aug. 01, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced financial …
Oculis Upsized Loan Facility to Access up to CHF 100 million
GlobeNewswire
·
August 1, 2025
ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet …
Diplomatic Trade Ltd, Thomas J. Kent Jr. the Kent Family Office, and Kent Global LLC Stake Acquisition in Turkish Pharma Firm, Target $300M UAE Biopharma Venture
GlobeNewswire
·
August 1, 2025
Thomas J. Kent Jr. DUBAI, United Arab Emirates, July 31, 2025 (GLOBE NEWSWIRE) -- Diplomatic Trade Ltd and Kent Global Support Strategic Stake in Turkish Pharma Group, Plan $300M UAE Biopharma Initiative Cross-border biopharma venture targets UAE facility …
Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds
GlobeNewswire
·
August 1, 2025
Cayman Islands, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced …